GHR
GHR is the transmembrane receptor mediating growth hormone signaling through JAK2/STAT5 and PI3K/AKT pathways. Loss-of-function mutations cause Laron syndrome and are associated with exceptional longevity and markedly reduced rates of cancer and diabetes.
Key Takeaways
- •GHR dictates the body's sensitivity to growth hormone, controlling the "Growth vs. Longevity" trade-off.
- •GHR deficiency (Laron Syndrome) confers profound protection against cancer and type 2 diabetes.
- •The d3-GHR variant increases GH sensitivity and is linked to exceptional longevity in men.
- •Fasting and caloric restriction dramatically modulate GHR signaling, lowering IGF-1 to promote repair.
Basic Information
- Gene Symbol
- GHR
- Full Name
- Growth Hormone Receptor
- Also Known As
- GHBPGH-binding protein
- Location
- 5p13.1-p12
- Protein Type
- Cytokine receptor (single-pass)
- Protein Family
- Type I cytokine receptor
Related Isoforms
Key SNPs
Common polymorphism (deletion of exon 3) associated with increased GH sensitivity and longevity in males.
Tag SNP often used to identify the d3-GHR variant in genetic studies.
Classic Laron Syndrome mutation (E180) in Ecuadorian cohort; causes receptor deficiency and severe short stature.
Isoform variant associated with potential modulation of signaling efficiency.
Overview
The Growth Hormone Receptor (GHR) is the gatekeeper of somatic growth. It sits on the surface of cells—most notably in the liver—waiting for pulses of Growth Hormone (GH) from the pituitary gland. When GH binds, GHR triggers a powerful signaling cascade that results in the production of IGF-1, the hormone responsible for most of the "growth" effects we associate with childhood and puberty.
However, GHR is not just about height. In adulthood, it regulates metabolism, body composition, and aging. There is a fundamental biological trade-off here: high GHR signaling promotes muscle and bone mass but accelerates aging and cancer risk. Conversely, low GHR signaling (as seen in Laron Syndrome) prevents cancer and diabetes but can lead to short stature and increased adiposity. Balancing this axis is a central theme in longevity science.
Conceptual Model
A simplified mental model for the pathway:
Laron Syndrome is like having a broken thermostat: the furnace (Pituitary) works overtime (high GH), but the radiator (Liver) never turns on (low IGF-1).
Core Health Impacts
- • Growth & skeletal frame: Determines final adult height and skeletal frame size.
- • Body fat distribution: Regulates body fat distribution (GHR activation burns visceral fat).
- • Systemic IGF-1 control: Controls systemic IGF-1 levels, a major driver of cell division.
- • Insulin sensitivity: Influences insulin sensitivity (chronic high GH causes insulin resistance).
- • Bone health: Affects fracture risk and bone mineral density in aging.
Protein Domains
Extracellular Domain
Binds GH. This part can be cleaved off to become GHBP (Growth Hormone Binding Protein), which circulates in blood and buffers GH action.
Transmembrane Domain
A single pass helix that transmits the "rotation" signal. When GH binds outside, the receptor twists, activating JAK2 inside.
Intracellular Box 1/2
The docking site for JAK2. Mutations here (or in JAK2) prevent the signal from ever starting, even if GH binds perfectly.
Upstream Regulators
Growth Hormone (GH) Activator
The primary ligand. GH binds to pre-formed GHR dimers, inducing a conformational change that activates signaling.
Ghrelin Activator
Hunger hormone that stimulates pituitary GH release, thereby increasing the ligand available for GHR.
Estrogen Activator
Modulates GH action; oral estrogen can inhibit hepatic IGF-1 production, leading to compensatory high GH levels.
Fasting Activator
Increases GH secretion pulses but uncouples the GHR-IGF1 axis (GH resistance), preserving glucose for the brain.
Sleep Activator
Deep slow-wave sleep triggers the largest pulses of GH secretion, activating GHR for tissue repair.
Downstream Targets
JAK2 Activates
Janus Kinase 2 is constitutively bound to GHR; it is the first enzyme activated upon ligand binding.
STAT5b Activates
The master effector. Phosphorylated by JAK2, it translocates to the nucleus to drive IGF-1 transcription.
IGF-1 Activates
The primary output of hepatic GHR signaling; mediates most growth-promoting effects of GH.
PI3K / AKT Activates
Activated by GHR to support cell survival and metabolic changes, often overlapping with insulin signaling.
MAPK / ERK Activates
Signaling branch involved in cell proliferation and mitogenesis downstream of GHR.
SOCS2/3 Inhibits
Suppressors of Cytokine Signaling; negative feedback proteins induced by STAT5b to turn off GHR signaling.
Role in Aging
The GHR is central to the "Antagonistic Pleiotropy" theory of aging: what is good for you when young (growth, high IGF-1) may be bad for you when old (cancer, cell senescence). Inhibiting GHR signaling has consistently extended lifespan in model organisms.
The Laron Paradox
People with Laron Syndrome (GHR deficiency) almost never get cancer or diabetes, despite often being obese. Disabling GHR shuts down major pro-cancer pathways.
IGF-1 & Lifespan
Lower levels of IGF-1 (downstream of GHR) correlate with longer lifespan in centenarians. Reducing GHR output shifts cells from "growth" to "repair/maintenance" mode.
Somatic Maintenance
Low GHR signaling upregulates stress resistance genes (like FOXO). This protects DNA and proteins from damage, slowing the accumulation of aging "junk."
Insulin Sensitivity
While GH itself causes insulin resistance, GHR deficiency (paradoxically) leads to extreme insulin sensitivity, protecting against metabolic syndrome.
Immunosenescence
GH stimulates the thymus. While high GH is good for immunity in youth, chronic high GH/IGF-1 in old age might accelerate immune exhaustion.
The d3-GHR Variant
A specific deletion in GHR (d3) increases sensitivity to GH. Surprisingly, this "super-receptor" is also associated with longevity in men, perhaps by allowing more effect with less hormone.
Disorders & Diseases
Laron Syndrome
A rare genetic disorder caused by GHR mutations. Characterized by severe short stature but remarkable protection against age-related diseases.
Acromegaly
Caused by a pituitary tumor secreting excess GH. Leads to GHR overactivation, resulting in bone overgrowth, diabetes, and heart failure. It is the functional opposite of Laron Syndrome.
Idiopathic Short Stature
Some cases are linked to heterozygous mutations in GHR or mild insensitivity. Treatment often involves high-dose recombinant GH to overcome the receptor resistance.
Metabolic Syndrome
Visceral obesity is often associated with "functional" GH deficiency (low GH, normal/high IGF-1 relative to GH). GHR signaling is blunted in obesity, contributing to fatty liver.
Interventions
Supplements
Used to stimulate acute GH release, though long-term effects on GHR signaling are debated.
Essential cofactors for proper GH synthesis and receptor structure stability.
May enhance sleep quality, indirectly supporting the nocturnal GH surge.
Lifestyle
Increases GH secretion (to preserve lean mass) while lowering IGF-1, creating a unique protective metabolic state.
Potent stimulus for acute GH release and local GHR activation in muscle tissue.
Crucial for GHR function, as the majority of GH signaling occurs during deep sleep cycles.
Acute heat exposure can transiently elevate growth hormone levels significantly.
Medicines
GHR antagonist used in acromegaly. Blocks GH binding and receptor rotation, preventing signaling.
Used to treat GH deficiency. Requires functional GHR to work (ineffective in Laron Syndrome).
Bypasses the GHR entirely; used for Laron Syndrome patients who cannot respond to GH.
Lab Tests & Biomarkers
Direct Measures
The gold standard for average GHR activity. Stable in blood, unlike pulsatile GH.
Growth Hormone Binding Protein. It's the cleaved extracellular part of GHR. Low GHBP often implies low GHR density.
Functional Tests
Provocative test (using insulin or arginine) to see if the pituitary can release GH.
Major carrier of IGF-1. Levels correlate with GH secretion and receptor function.
Genetic Testing
Testing for d3-GHR isoform. Relevant for predicting response to GH therapy and potential longevity.
Hormonal Interactions
Growth Hormone Primary Ligand
Pulsatile hormone from the pituitary that activates GHR to drive growth and metabolism.
IGF-1 Downstream Effector
Produced mainly in the liver via GHR; executes the "growth" signals on peripheral tissues.
Insulin Crosstalk Partner
GH is counter-regulatory to insulin (raises glucose), but IGF-1 has insulin-like effects.
Ghrelin Secretagogue
Stomach-derived hormone that drives the release of GH from the pituitary.
Somatostatin Inhibitor
Inhibits pituitary GH release, thereby reducing upstream activation of GHR.
Deep Dive
Network Diagrams
GHR-JAK2-STAT5 Signaling
Mechanism: The JAK-STAT Pathway
The GHR signaling cascade is a classic example of the JAK-STAT pathway, a direct line from the cell surface to the nucleus.
-
Ligand Binding & Dimerization: GHR exists on the cell membrane as a pre-formed dimer. When one GH molecule binds, it locks the two receptor halves into a specific alignment.
-
JAK2 Activation: This alignment brings the intracellular JAK2 kinases close enough to phosphorylate each other. Once active, JAK2 phosphorylates tyrosines on the GHR tail.
-
STAT5b Recruitment: These phosphorylated tyrosines act as magnets for STAT5b. STAT5b binds, gets phosphorylated by JAK2, dimerizes, and travels to the nucleus to turn on the IGF-1 gene.
The d3-GHR “Super-Receptor”
A common genetic variant involves the deletion of exon 3 (d3-GHR). Surprisingly, deleting this part of the receptor makes it more active, not less.
Structure: The deletion removes a section of the extracellular domain. This structural change alters how the receptor clusters on the membrane and interacts with GH.
Function: d3-GHR transduces the signal roughly 30% more effectively than the full-length (fl-GHR) version. Carriers of this variant grow taller on average and respond better to GH therapy.
Longevity: Paradoxically, while high GH is usually pro-aging, d3-GHR is enriched in male centenarians. One theory is that having a more sensitive receptor allows the pituitary to secrete less GH overall to achieve the same effect, sparing the body from the off-target metabolic stress of high circulating GH.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Identified the d3-GHR variant as a "super-receptor" associated with increased lifespan in men, likely due to enhanced signal efficiency.
Classic paper describing the molecular basis of Laron Syndrome as a GHR defect, leading to the discovery of the GHR itself.
Showed that humans with GHR deficiency (Laron Syndrome) are virtually immune to cancer and diabetes.
Established the GHR knockout mouse model (GHRKO), which lives remarkably longer than wild-type mice.
Clinical proof of principle that blocking GHR conformational change prevents downstream signaling and disease pathology.
Comprehensive review of how nutrient status uncouples GHR from IGF-1 production during fasting.